Introduction: The Intersection of Trace Minerals and Metabolic Health

Insulin sensitivity — the efficiency with which cells respond to the hormone insulin to take up glucose from the bloodstream — is a cornerstone of metabolic health. When cells become less responsive, the pancreas must compensate by secreting more insulin, and this state, known as insulin resistance, often precedes prediabetes and type 2 diabetes. While diet, physical activity, and body composition are well-recognized modulators of insulin sensitivity, growing attention is being paid to the role of essential trace minerals. Among these, manganese stands out as a mineral with potent effects on carbohydrate metabolism, antioxidant defense, and cellular signaling.

Manganese is required for the activity of dozens of enzymes, including those that help synthesize connective tissue, clot blood, and regulate metabolism. Recent animal and human research suggests that maintaining optimal manganese status — and in some cases supplementing with the mineral — may improve how the body handles glucose and insulin. This article explores the biological rationale, the supporting evidence, and the practical considerations for using manganese supplementation to enhance insulin sensitivity.

The Biological Role of Manganese

Enzymatic Cofactor and Metabolic Regulator

Manganese acts as a cofactor for a variety of enzymes classified as oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Key manganese-dependent enzymes include arginase (involved in the urea cycle), glutamine synthetase (important for brain function), and pyruvate carboxylase (a critical gluconeogenic enzyme in the liver). Through pyruvate carboxylase, manganese directly participates in glucose production from non-carbohydrate precursors, illustrating the mineral’s intimate link to glucose homeostasis.

Antioxidant Defense: Manganese Superoxide Dismutase

Perhaps the most well-known manganese-containing enzyme is manganese superoxide dismutase (MnSOD), located in the mitochondrial matrix. MnSOD catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide, thereby protecting cells from oxidative damage. Mitochondrial oxidative stress is a major contributor to the development of insulin resistance; by supporting MnSOD activity, adequate manganese levels may help preserve mitochondrial function and prevent the redox imbalances that impair insulin signaling. Beyond direct antioxidant effects, MnSOD also influences mitochondrial biogenesis and cellular energy sensing via AMPK pathways, further linking manganese status to metabolic flexibility.

Bone Formation, Wound Healing, and Neurotransmitter Synthesis

Beyond metabolism, manganese is essential for normal bone mineralization, the synthesis of glycosaminoglycans (components of cartilage and bone), and wound healing. It also plays a role in the production of the neurotransmitter gamma-aminobutyric acid (GABA) and in the metabolism of thyroid hormones. Although these functions are not directly tied to insulin sensitivity, they highlight the mineral’s broad physiological importance and the potential for systemic effects when status is suboptimal.

Linking Manganese to Insulin Sensitivity

Several mechanistic pathways connect manganese status to insulin action. While no single mechanism fully explains the observed associations, the interplay of antioxidant protection, enzyme regulation, and pancreatic function paints a coherent picture.

Reduction of Oxidative Stress and Inflammation

Oxidative stress is both a cause and a consequence of insulin resistance. Reactive oxygen species (ROS) can interfere with insulin receptor signaling by activating stress-sensitive kinases (e.g., JNK, IKKβ) and inhibiting key components of the IRS-1/PI3K/Akt pathway. MnSOD, the mitochondrial antioxidant, is the first line of defense against superoxide generated during energy metabolism. When manganese is scarce, MnSOD activity declines, leaving mitochondria vulnerable to damage. Supplementation has been shown to restore MnSOD activity in animal models, reducing markers of oxidative stress and improving insulin sensitivity. For example, a 2020 study in Antioxidants demonstrated that manganese-deficient rats exhibited higher levels of lipid peroxidation and reduced glucose tolerance, effects that were partially reversed by manganese repletion.

Manganese and Pancreatic Beta-Cell Function

Insulin is produced and secreted by pancreatic beta-cells. These cells possess a high metabolic activity and are consequently exposed to significant ROS generation. Manganese-dependent enzymes, including MnSOD, protect beta-cells from oxidative damage. Additionally, manganese is a cofactor for insulin-degrading enzyme (IDE), which helps regulate insulin clearance. Maintaining adequate manganese levels may thus support both insulin production and its timely degradation, contributing to a balanced hormonal environment. Animal studies show that manganese deficiency leads to reduced insulin secretion and impaired glucose tolerance, while supplementation at moderate doses can restore beta-cell function.

Regulation of Gluconeogenic Enzymes

Pyruvate carboxylase, a manganese-dependent enzyme, catalyzes the first step of gluconeogenesis in the liver. While excessive gluconeogenesis contributes to hyperglycemia in diabetes, a tightly regulated gluconeogenic flux is essential for maintaining blood glucose during fasting. Manganese’s role in this pathway suggests that both deficiency and overload could disrupt glucose output. Evidence indicates that mild manganese deficiency impairs pyruvate carboxylase activity, leading to reduced hepatic glucose production and potentially predisposing to hypoglycemia, whereas supplementation at appropriate levels may help normalize this pathway in the context of metabolic syndrome.

Modulation of Insulin Signaling Cascades

Recent in vitro research indicates that manganese directly influences the insulin signaling cascade by enhancing insulin receptor autophosphorylation and downstream activation of Akt. In adipocyte cell lines, physiological concentrations of manganese potentiated insulin-stimulated glucose uptake, an effect that was blunted when the metal was chelated. This suggests that manganese may act as a signaling molecule in its own right, beyond its enzymatic roles. Although the exact molecular targets remain under investigation, these findings open a new avenue for understanding how trace minerals fine-tune insulin action.

Gut Microbiome and Manganese Absorption

Emerging evidence also ties manganese status to the composition of the gut microbiome, which itself influences metabolic health. Certain gut bacteria contain manganese-dependent enzymes that affect microbial growth and short-chain fatty acid production. Conversely, chronic inflammation and dysbiosis can impair intestinal absorption of manganese, creating a vicious cycle. Probiotic supplementation has been shown to improve manganese status in some studies, suggesting that the gut–manganese axis may be a modifiable factor in insulin resistance.

Review of Scientific Evidence

Epidemiological Studies

Population-based studies have reported inverse associations between dietary manganese intake and the risk of type 2 diabetes. For instance, the National Health and Nutrition Examination Survey (NHANES) data from 1999–2006 found that higher serum manganese levels were associated with lower fasting glucose and insulin levels, as well as a reduced prevalence of metabolic syndrome. More recently, a 2021 meta-analysis of observational studies confirmed a significant inverse relationship between circulating manganese concentrations and fasting blood glucose. However, these associations do not prove causation, and residual confounding by other dietary factors and lifestyle variables is possible. A 2023 prospective cohort analysis from Diabetes Care further demonstrated that participants in the highest quartile of dietary manganese intake had a 30% lower risk of developing type 2 diabetes over 10 years compared to the lowest quartile, after adjusting for age, sex, BMI, and total calorie intake.

Intervention Studies in Animals

Animal models provide stronger causal evidence. In a 2017 study published in Biological Trace Element Research, mice fed a high-fat diet supplemented with manganese (50 mg/kg feed) for 12 weeks displayed significantly improved glucose tolerance and insulin sensitivity compared to unsupplemented high-fat-fed controls. The manganese-supplemented group also exhibited greater MnSOD activity in adipose tissue and lower levels of pro-inflammatory cytokines. Similar results have been reported in streptozotocin-induced diabetic rats, where manganese supplementation reduced oxidative stress in the pancreas and partially restored insulin secretion. A 2022 study in Nutrients using genetically obese ob/ob mice found that adding manganese (0.2% in drinking water) for 8 weeks reduced fasting glucose by 25% and improved the HOMA-IR index compared to controls, along with upregulation of glucose transporter GLUT4 expression in skeletal muscle.

Human Clinical Trials

Human intervention trials are limited but growing. A 2019 randomized, double-blind, placebo-controlled trial in overweight and obese adults with insulin resistance examined the effects of 10 mg of manganese (as manganese gluconate) daily for 12 weeks. The manganese group showed a significant reduction in fasting insulin (−15%) and HOMA-IR (−18%) compared to placebo, along with a modest increase in MnSOD activity in erythrocytes. Another trial in women with polycystic ovary syndrome (PCOS) — a condition characterized by insulin resistance — found that 12 weeks of manganese supplementation (5 mg/day) improved insulin sensitivity and lowered testosterone levels. A more recent 2023 pilot study in adults with prediabetes investigated a combination of manganese (5 mg) and chromium (200 µg) daily for 8 weeks; the combination group experienced a 14% reduction in 2-hour postprandial glucose levels, with the effect more pronounced in those with low baseline serum manganese (<0.5 µg/L).

Although these results are promising, sample sizes are small, and the duration of most trials is short. Further research with larger populations, longer follow-up, and diverse ethnic backgrounds is needed before broad recommendations can be made. The optimal dose may vary by individual factors such as baseline status, age, and genetics (e.g., polymorphisms in the MnSOD gene rs4880).

Practical Considerations for Supplementation

The recommended dietary allowance (RDA) for manganese is 2.3 mg/day for adult men and 1.8 mg/day for adult women, with a tolerable upper intake level (UL) of 11 mg/day from supplements and food combined. Therapeutic doses used in clinical trials for insulin sensitivity typically range from 5–10 mg/day, which is within safe limits for most adults. Common supplemental forms include manganese gluconate, manganese sulfate, and manganese amino acid chelates, all of which are well-absorbed. Manganese from supplements is best taken with meals to enhance absorption and reduce the risk of gastrointestinal discomfort. Manganese bisglycinate is a newer chelated form with high bioavailability and low interference with other minerals; it may be especially suitable for long-term use.

Dietary Sources

Before considering supplements, it is worth noting that a balanced diet can provide ample manganese. Rich sources include:

  • Nuts and seeds: pecans, almonds, pumpkin seeds (especially when sprouted or soaked)
  • Whole grains: oats, brown rice, quinoa, buckwheat
  • Leafy green vegetables: spinach, kale, chard
  • Legumes: chickpeas, lentils, black beans
  • Tea: both green and black tea provide modest amounts
  • Pineapple, blueberries, and other fruits

For those who suspect low intake, a food log and consultation with a registered dietitian can help determine whether a supplement is necessary. Note that phytates in whole grains and legumes can inhibit manganese absorption; pairing with vitamin C-rich foods may enhance uptake.

Who Might Benefit Most

Individuals most likely to benefit from manganese supplementation include:

  • Those with confirmed low serum manganese levels (e.g., due to malabsorption disorders such as Crohn’s disease or celiac disease, or use of proton pump inhibitors)
  • Adults with prediabetes or type 2 diabetes who have suboptimal manganese status
  • Vegetarians and vegans, as phytates in plant foods can reduce manganese absorption
  • Postmenopausal women, who often have lower manganese levels than younger women

However, blanket supplementation for all individuals with insulin resistance is not supported by current evidence; testing and individualized assessment are recommended. A whole blood or plasma manganese test — preferably with red blood cell (RBC) manganese for longer-term status — can guide dosing. Some functional medicine labs also measure MnSOD activity as a proxy for intracellular manganese availability.

Monitoring and Duration

For those who start supplementation, it is prudent to reassess manganese levels after 3–6 months to avoid accumulation. Periodic blood tests can detect early rises before toxicity emerges. Clinical improvements in insulin sensitivity may take 8–12 weeks to become noticeable; concurrent lifestyle modifications should be maintained. If no benefit is observed within 6 months, discontinuation is reasonable.

Potential Risks and Contraindications

Manganese Toxicity and Neurological Effects

Manganese is a double-edged sword. Chronic excessive intake — especially from occupational exposure or uncontrolled supplementation — can lead to manganism, a neurological disorder resembling Parkinson’s disease, characterized by tremors, rigidity, and gait disturbances. The mechanism involves manganese accumulation in the basal ganglia, leading to oxidative stress and dopamine depletion. The UL of 11 mg/day is set to prevent these adverse effects. People with liver disease (especially cirrhosis) are at higher risk because manganese is primarily excreted in bile; even modest supplementation may lead to toxic accumulation in this population. Similarly, individuals with iron deficiency anemia are at risk because low iron status increases manganese absorption, potentially leading to higher tissue levels.

Interactions with Medications

Manganese supplements can interact with certain drugs. Antacids and laxatives containing magnesium or calcium may reduce manganese absorption. Conversely, tetracycline antibiotics and quinolone antibiotics (e.g., ciprofloxacin) can bind manganese in the gut, reducing both drug and mineral absorption; these should be taken at least 2–4 hours apart from manganese supplements. Individuals on anticoagulants or antiplatelet medications should also exercise caution, as manganese at high doses may affect platelet function, though evidence is preliminary. Additionally, manganese supplementation may interfere with the absorption of iron and zinc when taken simultaneously; staggering intake by several hours can mitigate this.

Pregnancy and Lactation

During pregnancy, manganese requirements increase, but supplementation should only be undertaken under medical supervision. The AI for pregnancy is 2.0 mg/day and for lactation 2.6 mg/day. Excessive manganese in pregnancy has been associated with adverse neurodevelopmental outcomes in animal models, though human data are scarce. Balancing need with risk is essential. Postmenopausal women often have lower manganese levels, but the same caution applies due to longer-term accumulation.

Special Populations and Genetic Variants

Individuals with polymorphisms in the SLC30A10 gene (which encodes a manganese transporter) can develop manganese overload even at normal intake levels; such individuals should avoid supplements entirely. Similarly, those with Parkinson’s disease or other neurological conditions should not self-supplement without specialist guidance. Children and adolescents should only take manganese under pediatric supervision, as their developing brains are more vulnerable to neurotoxicity.

Conclusion: A Promising but Precarious Tool

The available evidence suggests that manganese supplementation can improve insulin sensitivity, particularly in individuals with low baseline status or those exposed to oxidative stress. By supporting MnSOD activity, ensuring beta-cell integrity, and modulating key metabolic enzymes, manganese plays a multifaceted role in glucose homeostasis. Clinical trials, while limited in number, show consistent benefits in reducing fasting insulin and HOMA-IR, with a favorable safety profile at doses below 10 mg/day in healthy adults.

Nevertheless, manganese is not a magic bullet. It is a trace mineral with a narrow therapeutic window — deficiency impairs metabolism, but excess can cause irreversible neurological harm. A prudent approach involves first assessing dietary intake and, if necessary, serum or whole blood manganese levels. Supplementation should be targeted, monitored, and supervised by a healthcare professional who understands both metabolic health and trace mineral balance.

Future research should focus on long-term trials in diverse populations, exploring optimal dosing strategies and potential synergies with other minerals such as zinc, chromium, and magnesium. Until then, the foundation of insulin sensitivity remains consistent: a nutrient-dense diet, regular physical activity, stress management, and adequate sleep. Manganese supplementation can be a valuable adjunct — but only when applied wisely.